VSee Health Announces Strategic Review as Board Advances Late-Stage Strategic Discussions to Maximize Shareholder Value

VSee Health (NASDAQ:VSEE) said it signed a non-binding letter of intent to acquire healthcare technology and operating assets for a vertically integrated healthcare commerce platform. VSee estimates the deal value at about $42 million, with target annualized revenue over $35 million and about $7 million EBITDA, unaudited. Closing depends on due diligence, definitive agreements, and approvals.

VSee Health, Inc. signed a non-binding LOI to acquire healthcare technology and operating assets valued at about $42 million. The target supports a clinic-based wellness commerce platform with an unaudited annual revenue run rate over $35 million and about $7 million in EBITDA. VSee says it would integrate ordering and payment workflows into its API virtual care platform, subject to due diligence and approvals.

VSee Health (NASDAQ:VSEE) said it entered a non-binding letter of intent to acquire certain healthcare technology and operating assets for a vertically integrated healthcare commerce platform. The target assets have an unaudited run rate above $35 million and EBITDA around $7 million. VSee expects a quick close without initial shareholder dilution, subject to due diligence and definitive agreements.

VSee Health (NASDAQ:VSEE) said it entered a non-binding letter of intent to acquire certain healthcare technology and operating assets for $42 million. The target assets have an unaudited run rate above $35 million in annualized revenue and about $7 million in EBITDA. VSee will conduct due diligence and negotiate definitive terms; no deal is assured.

VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 3 vseeex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VSEE HEALTH, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with

H.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.